Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

What are GLP-1 agonists? GLP-1 agonists, also known as incretin mimetics, are a class of medication that is primarily used to treat type 2 diabetes and, in some cases, obesity. "T ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving glucagon-like peptide 1 receptor agonists (GLP-1 RAs) within the context of ...

The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but have opposite effects on chylomicron (CM) production, with GLP-1 ...

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...

Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...

BPC-157 is said to help joint recovery. Glucagon-like Peptide-1 (GLP-1) is utilized in the treatment of type 2 diabetes and obesity, as it signals the pancreas to increase the production of ...

“Normally, the large size of an anti-KRAS antibody prevents it from penetrating ... such as parathyroid hormone (PTH) or glucagon-like peptide-1 (GLP-1) receptor agonists. Such drugs are ...

While it had to discontinue the development of one of its glucagon-like peptide-1 receptor agonist (GLP-1 ... pipeline with a $43bn acquisition of the antibody-drug conjugate specialist Seagen ...

a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting ...